Holen Sie sich die Stockscreener-App
31.83
1.82%
0.57
Vorhandelsmarkt:
31.98
0.15
+0.47%
Schlusskurs vom Vortag:
$31.26
Offen:
$31.5
24-Stunden-Volumen:
378.60K
Relative Volume:
0.42
Marktkapitalisierung:
$1.84B
Einnahmen:
$868.45M
Nettoeinkommen (Verlust:
$158.69M
KGV:
11.75
EPS:
2.7087
Netto-Cashflow:
$328.64M
1W Leistung:
+3.34%
1M Leistung:
+13.84%
6M Leistung:
+11.41%
1J Leistung:
+6.60%
1-Tages-Spanne:
$31.02
$31.86
1-Wochen-Bereich:
$30.45
$31.86
52-Wochen-Spanne:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
31.83 | 1.84B | 868.45M | 158.69M | 328.64M | 2.7087 |
VRTX
Vertex Pharmaceuticals Inc
|
423.92 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.42 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
783.50 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.11 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
293.86 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Herabstufung | Truist | Buy → Hold |
| 2026-02-11 | Fortgesetzt | UBS | Neutral |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
CX Institutional Increases Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Capital Management Corp VA Sells 41,191 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
HRMY stock on track for best intraday gains in 18 months — what did Mizuho analysts say? - MSN
Price-Driven Insight from (HRMY) for Rule-Based Strategy - Stock Traders Daily
Earnings Preview: HRMY to Report Financial Results Pre-market on May 07 - Moomoo
M3Sixty Small Cap Growth Fund's Harmony Biosciences Holdings Inc(HRMY) Holding History - GuruFocus
Harmony Bio spikes after new Wakix patent litigation - MSN
Harmony Biosciences (HRMY) Projected to Post Quarterly Earnings on Thursday - MarketBeat
A Look At Harmony Biosciences (HRMY) Valuation After CFO Appointment And Reaffirmed 2026 Revenue Outlook - Sahm
Top 5 US Stocks To Buy In May 2026 - Investing.com
Q3 Earnings Estimate for HRMY Issued By HC Wainwright - MarketBeat
Harmony Biosciences Appoints Glenn Reicin as CFO, Reaffirms Outlook - MyChesCo
Assessing Harmony Biosciences (HRMY) Valuation After Recent Share Price Momentum And Pipeline Expectations - Yahoo Finance
H.C. Wainwright reiterates Harmony Biosciences stock rating on IP litigation outlook By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Harmony Biosciences stock rating on IP litigation outlook - Investing.com Australia
Research Analysts Issue Forecasts for HRMY Q1 Earnings - MarketBeat
Why Harmony Biosciences (HRMY) Reaffirmed 2026 Revenue Guidance and Hired a Markets-Focused CFO - Yahoo Finance
Harmony Biosciences (HRMY) Attracts Buy Rating Amid IP Litigatio - GuruFocus
Harmony Bio granted FDA label expansion for Wakix in children with narcolepsy - MSN
Harmony Biosciences Holdings, Inc. (HRMY) Latest Stock News & Headlines - Yahoo Finance
Press Release: Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - 富途牛牛
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Crescent Biopharma (CBIO) - The Globe and Mail
Ruffer LLP Purchases Shares of 40,993 Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Legend Biotech (LEGN) moves 18.4% higher: Will this strength last? - MSN
Oppenheimer raises Harmony Biosciences stock price target on patent strength - Investing.com
Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed? - simplywall.st
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $72 at Oppenheimer - StreetInsider
HRMY.O - Reuters
HRMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Harmony Biosciences (HRMY) Shares Rise on Positive Patent Litiga - GuruFocus
HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits
Harmony Biosciences (HRMY) Secures Patent Lawsuit Against Generi - GuruFocus
Harmony (HRMY) Sees 14% Surge Following Patent Lawsuit Discovery - GuruFocus
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):